The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Gastroenterology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Sat, 10 Oct 2026 23:05:39 GMT 2026 NEJM Group en-us 1440 The efficacy and popularity of GLP-1 agents have sparked a race to develop increasingly potent therapies. But protections for people enrolled in trials of investigational products may be inadequate. https://www.nejm.org/doi/full/10.1056/NEJMp2609407?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2609407 Sarah H. Schmitz 2026-10-08 Beyond Percentage of Weight Lost — Protecting Participants in Obesity Trials In this phase 3, double-blind, placebo-controlled trial involving adults with obesity and type 2 diabetes, the investigational glucagon receptor–GLP-1 receptor dual agonist survodutide led to significant weight reduction. https://www.nejm.org/doi/full/10.1056/NEJMoa2607219?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2607219 Sean Wharton, Carel W. le Roux, Elena Startseva, Isabel M. Kloer, Ahmad Alhussein, Samina Ajaz Hussain, Anna Unseld, Biykem Bozkurt, Jamy D. Ard, Harold E. Bays, Paweł Bogdański, Jawad H. Butt, Elif I. Ekinci, Ania M. Jastreboff, Linong Ji, Morten Schou, Francisco J. Tinahones, Alexander D. Kokkinos, Béla Merkely, Wataru Ogawa, Sue D. Pedersen, Kirsi H. Pietiläinen, Dean Quinn, Naveed Sattar, Jochen Seufert, Kaj Stenlöf, André P. van Beek, Roman Vangoitsenhoven, Martina Brueckmann, Ramy Younes, Lee M. Kaplan, the SYNCHRONIZE-2 Investigators* 2026-10-01 Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes When a robust long-time patient with chronic pain and heavy alcohol use declines precipitously after a complicated hospital course, her medical team must find a way to revive her old self. https://www.nejm.org/doi/full/10.1056/NEJMp2603393?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2603393 Michael A. Incze, Laura Stolebarger 2026-10-01 The Mayor In this trial involving participants with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. https://www.nejm.org/doi/full/10.1056/NEJMoa2604169?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2604169 Ania M. Jastreboff, Lee M. Kaplan, Melanie J. Davies, John P.H. Wilding, Nadia N. Ahmad, Megan Murray, Yu Du, Nune Makarova, Kathryn Giblin, Nanette C. Schloot, Yan Wang, the TRIUMPH-1 Investigators* 2026-09-29 Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity In this planned interim analysis of a randomized trial, first surveillance colonoscopy at 5 years after the removal of high-risk adenomas was noninferior to first colonoscopy at 3 years for the incidence of colorectal cancer. https://www.nejm.org/doi/full/10.1056/NEJMoa2603816?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2603816 Rodrigo Jover, Michael Bretthauer, Joaquin Cubiella, Sarah J.E. Barry, Anna Macios, Lauren Barnett, Rune Erichsen, Michal F. Kaminski, Hans-Olov Adami, Øyvind Holme, Joep Ijspeert, Monika Ferlitsch, Mario Dinis-Ribeiro, Maria Pellise, Alejandro Martínez-Roca, Sandra Baile-Maxía, Luisa de-Castro, Luis Bujanda, Pilar Díez-Redondo, Jens Aksel Nordberg Nilsen, Hong Dung Nguyen, Linn Bernklev, Jørgen Tilma, Uffe Schou Løve, Claudia Jaensch, Nastazja D. Pilonis, Mirosław Szura, Andrzej Bialek, Annemarie van Berkel, Manon C.W. Spaander, Frank ter Borg, Monique E. van Leerdam, Miguel A. Hernán, Jaroslaw Regula, Magnus Løberg, Evelien Dekker, Mette Kalager, the EPoS Study Group* 2026-09-17 Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal For patients with esophageal cancer, 5-year survival has improved in recent decades but rarely exceeds 20%. This review summarizes risk factors, screening, and treatment for the two main histologic types. https://www.nejm.org/doi/full/10.1056/NEJMra2516631?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2516631 Shao-Hua Xie, Elizabeth Smyth, Jesper Lagergren 2026-09-17 Esophageal Cancer This feature about colorectal cancer screening in a 46-year-old man offers a case vignette accompanied by two essays, one recommending screening by colonoscopy and the other supporting use of a stool-based test. https://www.nejm.org/doi/full/10.1056/NEJMclde2600695?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMclde2600695 Alejandro Campos, Aasma Shaukat, Douglas J. Robertson 2026-09-17 Initial Screening for Colorectal Cancer A 72-year-old man with hypertension, hyperlipidemia, and a stable ascending aortic aneurysm presented with sudden-onset, severe chest pain. CTA of the chest, abdomen, and pelvis showed a celiac-artery dissection. https://www.nejm.org/doi/full/10.1056/NEJMicm2605936?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2605936 Akshat Agrawal, Kimberly Foust 2026-09-17 Celiac-Artery Dissection Colonoscopy surveillance after the removal of adenomas is a cornerstone of the prevention of colorectal cancer. Guidelines in the United States and Europe have endorsed surveillance beginning at 3 years after the removal of advanced adenomas (defined as ≥1 adenoma with a diameter of ≥10 mm, high-grade dysplasia, or villous... https://www.nejm.org/doi/full/10.1056/NEJMe2608876?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2608876 Aasma Shaukat, Theodore R. Levin 2026-09-17 When More Is Not Better — Colonoscopy Surveillance after High-Risk Adenomas In this prospective trial, patients with serrated polyps had a low 5-year risk of colorectal cancer (1.0%). https://www.nejm.org/doi/full/10.1056/NEJMc2605026?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2605026 Evelien Dekker, Rodrigo Jover, Joep Ijspeert, Michael Bretthauer, for the EPoS Study Group* 2026-09-17 Colorectal Cancer Risk among Patients with Serrated Polyps A 46-year-old man with cirrhosis presented with a 1-week history of left flank pain. Physical examination was notable for a large ecchymosis on the left flank that was tender to palpation. https://www.nejm.org/doi/full/10.1056/NEJMicm2605791?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2605791 Kan-Ru Li, Chien Hao Lin 2026-09-10 Grey Turner’s Sign A 3-year-old boy with chemotherapy-resistant metastatic hepatoblastoma had complete regression lasting at least 12 months after two infusions of glypican-3–specific CAR T cells coexpressing interleukin-15 and interleukin-21. https://www.nejm.org/doi/full/10.1056/NEJMc2605958?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2605958 David Steffin, Amy N. Courtney, Michelle Choe, Nisha Ghatwai, Magdalena A. Esparza Cerda, Ramy Sweidan, Rajdekar Dhanashree, Huimin Zhang, Natasha Lapteva, Zhuyong Mei, Bambi J. Grilley, Leonid S. Metelitsa, Helen E. Heslop, Malcolm K. Brenner, Andras Heczey 2026-09-10 Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy This article describes gene editing in a mouse model of a peroxisomal disorder, as well as the broader landscape, including regulation, of the treatment of rare genetic disease through gene editing. https://www.nejm.org/doi/full/10.1056/NEJMcibr2606991?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcibr2606991 Rebecca C. Ahrens-Nicklas 2026-08-13 Gene Editing, Peroxisomal Disorders, and Treatments for Rare Disease A study noted a sharp increase in leucovorin prescriptions dispensed to children (≤17 years of age) after a plan was announced to update the FDA drug label to include cerebral folate deficiency, which may include autism symptoms. https://www.nejm.org/doi/full/10.1056/NEJMc2602260?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2602260 Kao-Ping Chua, Sijia He, Rena M. Conti 2026-08-13 Leucovorin Dispensing to U.S. Children in 2025 A 60-year-old man presented with a 1-month history of postprandial epigastric pain. CT of the abdomen showed a diffusely enlarged pancreas with a capsule-like rim. Serum levels of IgG4 were elevated. https://www.nejm.org/doi/full/10.1056/NEJMicm2604806?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2604806 Atsuto Kayashima, Masayasu Horibe 2026-08-06 Type 1 Autoimmune Pancreatitis Alternative complement pathway overactivation contributes to IgA nephropathy. In a placebo-controlled trial, iptacopan, a complement factor B inhibitor, significantly slowed kidney-function decline in patients with IgA nephropathy. https://www.nejm.org/doi/full/10.1056/NEJMoa2600743?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2600743 Jonathan Barratt, Necmi Eren, Naoki Kashihara, Bart Maes, Dana V. Rizk, Brad Rovin, Hernán Trimarchi, Hong Zhang, Weiming Wang, Ismail Kocyigit, Chuanming Hao, Vladimir Tesař, Kenan Turgutalp, Li Yang, Guangqun Xing, Valter Duro Garcia, Seung Hyeok Han, Wanhong Lu, Antonio Pisani, Julia Weinmann-Menke, Frank Eitner, Nicolas Guerard, Dmytro Butylin, Luca Monaco, Emil Scosyrev, Annabel Magirr, Ronny Renfurm, Thomas Hach, Vlado Perkovic, the APPLAUSE-IgAN Study Group* 2026-07-30 Iptacopan in IgA Nephropathy — Final 24-Month Data A 51-year-old woman with right heart failure presented with worsening abdominal distention and leg swelling. Examination was notable for ascites, leg edema, a grade 4/6 holosystolic murmur, and a pulsatile liver (shown in a video). https://www.nejm.org/doi/full/10.1056/NEJMicm2601392?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2601392 André Vaz, Lucas Araújo 2026-07-30 Pulsatile Liver in Severe Tricuspid Regurgitation Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2605555?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2605555 Eileen M. O’Reilly, Zev A. Wainberg, Andrew E. Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal Hammel, Chiara Cremolini, Gulam A. Manji, Paul E. Oberstein, Ignacio Garrido-Laguna, Christoph Springfeld, Nilofer S. Azad, Makoto Ueno, Stephen Y. Chui, Ying Zhang, Hina Patel, Yeonju Lee, Zeena Salman, Brian M. Wolpin, the RASolute 302 Trial Investigators* 2026-07-23 Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer The United States could take meaningful steps toward eliminating hepatitis C by broadly testing and treating people who are involved in the criminal legal system. https://www.nejm.org/doi/full/10.1056/NEJMp2602773?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2602773 Josiah D. Rich, Karla Thornton, Matthew J. Akiyama 2026-07-23 National Elimination of Hepatitis C — The Case for Starting in Prisons and Jails For decades, pancreatic ductal adenocarcinoma (PDAC) has been perhaps the clearest example of a cancer that is driven by a dominant oncogenic event yet is resistant to therapeutic exploitation. More than 90% of pancreatic cancers harbor activating RAS mutations, most commonly those involving KRAS codon 12,... https://www.nejm.org/doi/full/10.1056/NEJMe2606948?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2606948 Shivan Sivakumar 2026-07-23 Breaking the RAS Barrier in Pancreatic Cancer